EMA Authorised: Edistride (dapagliflozin propanediol monohydrate) — AstraZeneca AB

View source ↗

Summary

The European Medicines Agency authorised Edistride, a dapagliflozin propanediol monohydrate medicine by AstraZeneca, for type 2 diabetes mellitus, heart failure…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Heart Failure
• Type 2 Diabetes Mellitus

Drugs mentioned

• Edistride (dapagliflozin propanediol monohydrate)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2;Heart Failure, Systolic;Heart Failure;Renal Insufficiency, Chronic. MAH: AstraZeneca AB. Decision date: 12/03/2026